Dosage of Fleximat in details
When Fleximat administered orally for replacement therapy in adults the initial dose is 20-30 mg, maintenance dose is 10.5 mg / day. If necessary, the initial dose is may be 15-100 mg / day, the maintenance one is 5-15 mg / day. The daily dose should be reduced gradually. For children the starting dose is 1-2 mg / kg in 4-6 receptions, the maintenance one is 300-600 mg / kg / day.
For IM or IV dose administration the multiplicity and duration of application are determined individually.
When intra-articular administration in large joints it used a dose of 25-50 mg, for medium-sized joints - 10-25 mg for small joints - 5-10 mg. For the introduction of infiltration into the tissues depending on disease severity and magnitude of the defeat use doses from 5 mg to 50 mg.
Fleximat used topically in ophthalmology 3 times / day, course of treatment is no more than 14 days; in dermatology - 1-3 times / day.
Fleximat interactions
When this drug applied simultaneously with:
- digoxin slightly increased concentration of digoxin in plasma.
- itraconazole greatly increases the concentration of atorvastatin in plasma, apparently due to inhibition of itraconazole its metabolism in the liver that occurs with the participation of isoenzyme CYP3A4; increased risk of myopathy.
- colestipol may decrease the concentration of atorvastatin in plasma, with lipid-lowering effect is enhanced.
- antacids containing magnesium hydroxide and aluminum hydroxide, reduce the concentration of atorvastatin by approximately 35%.
- cyclosporine, fibrates (including gemfibrozil), azole antifungals derivatives, nicotinic acid increases the risk of myopathy.
- erythromycin, clarithromycin moderately increased concentrations of atorvastatin in plasma, increases the risk of myopathy.
- ethinyl estradiol, norethisterone (norethindrone) slightly increases the concentration of ethinyl estradiol, norethisterone and (norethindrone) in blood plasma.
- protease inhibitors increases the concentration of Eto in plasma, as protease inhibitors are inhibitors of the CYP3A4 isoenzyme.
Diltiazem, verapamil, isradipine inhibit isoenzyme CYP3A4, which participates in the metabolism of Eto, so that while the use of these calcium channel blockers may increase the concentration of atorvastatin in plasma and increased risk of myopathy.
References
- FDA/SPL Indexing Data. "KZF0XM66JC: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Inflammatory Agents, Non-Steroidal". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Etofenamate: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Fleximat are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Fleximat. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
